Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series

被引：2
作者：
Nikanjam, Mina [1 ]
Mullen, Jaren [1 ]
Yacoub, Carol [2 ]
Daniels, Gregory A. [1 ]
机构：
[1] Univ Calif San Diego, Div Hematol Oncol, 3855 Hlth Sci Dr 0987, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Moores Canc Ctr Clin Pharm, 3855 Hlth Sci Dr 0987, La Jolla, CA 92093 USA
来源：
JOURNAL OF MEDICAL CASE REPORTS | 2022年 / 16卷 / 01期
关键词：
Interleukin-2; Anti-PD-1; Metastatic melanoma; Case report; THERAPY;
D O I：
10.1186/s13256-022-03536-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background Therapeutic options are needed for metastatic melanoma refractory to therapies directed against programmed cell death-1. High-dose interleukin-2 has the potential to overcome programmed cell death-1 resistance. Case presentation We report three consecutive Caucasian patients, two female (60 and 55 years old) and one male (56 years old), refractory to anti-programmed cell death-1 therapy who were treated with concurrent nivolumab and standard-dosing bolus high-dose interleukin-2. We did not see any unexpected toxicities with overlapping treatments as compared with either high-dose interleukin-2 or nivolumab alone. Conclusions The tolerance and disease control observed among the three patients in this limited series support formal exploration of this combination.
引用
收藏
页数：5
相关论文
共 10 条
  • [1] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    Atkins, MB
    Lotze, MT
    Dutcher, JP
    Fisher, RI
    Weiss, G
    Margolin, K
    Abrams, J
    Sznol, M
    Parkinson, D
    Hawkins, M
    Paradise, C
    Kunkel, L
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116
  • [2] Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
    Blackburn, Shawn D.
    Shin, Haina
    Freeman, Gordon J.
    Wherry, E. John
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (39) : 15016 - 15021
  • [3] Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
    Buchbinder, Elizabeth I.
    Dutcher, Janice P.
    Daniels, Gregory A.
    Curti, Brendan D.
    Patel, Sapna P.
    Holtan, Shernan G.
    Miletello, Gerald P.
    Fishman, Mayer N.
    Gonzalez, Rene
    Clark, Joseph I.
    Richart, John M.
    Lao, Christopher D.
    Tykodi, Scott S.
    Silk, Ann W.
    McDermott, David F.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
    Buchbinder, Elizabeth I.
    Gunturi, Anasuya
    Perritt, Jessica
    Dutcher, Janice
    Aung, Sandra
    Kaufman, Howard L.
    Ernstoff, Marc S.
    Miletello, Girald P.
    Curti, Brendan D.
    Daniels, Gregory A.
    Patel, Sapna P.
    Kirkwood, John M.
    Hallmeyer, Sigrun
    Clark, Joseph I.
    Gonzalez, Rene
    Richart, John M.
    Lutzky, Joe
    Morse, Michael A.
    Sullivan, Ryan J.
    McDermott, David F.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [5] Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
    Diab, Adi
    Tannir, Nizar M.
    Bentebibel, Salah-Eddine
    Hwu, Patrick
    Papadimitrakopoulou, Vassiliki
    Haymaker, Cara
    Kluger, Harriet M.
    Gettinger, Scott N.
    Sznol, Mario
    Tykodi, Scott S.
    Curti, Brendan D.
    Tagliaferri, Mary A.
    Zalevsky, Jonathan
    Hannah, Alison L.
    Hoch, Ute
    Aung, Sandra
    Fanton, Christie
    Rizwan, Ahsan
    Iacucci, Ernesto
    Liao, Yijie
    Bernatchez, Chantale
    Hurwitz, Michael E.
    Cho, Daniel C.
    [J]. CANCER DISCOVERY, 2020, 10 (08) : 1158 - 1173
  • [6] Overview of interleukin-2 function, production and clinical applications
    Gaffen, SL
    Liu, KD
    [J]. CYTOKINE, 2004, 28 (03) : 109 - 123
  • [7] Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]
  • [8] Systemic Therapy of Metastatic Melanoma: On the Road to Cure
    Steininger, Julian
    Gellrich, Frank Friedrich
    Schulz, Alexander
    Westphal, Dana
    Beissert, Stefan
    Meier, Friedegund
    [J]. CANCERS, 2021, 13 (06) : 1 - 28
  • [9] Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
    Tawbi, Hussein A.
    Schadendorf, Dirk
    Lipson, Evan J.
    Ascierto, Paolo A.
    Matamala, Luis
    Gutierrez, Erika Castillo
    Rutkowski, Piotr
    Gogas, Helen J.
    Lao, Christopher D.
    De Menezes, Juliana Janoski
    Dalle, Stephane
    Arance, Ana
    Grob, Jean-Jacques
    Srivastava, Shivani
    Abaskharoun, Mena
    Hamilton, Melissa
    Keidel, Sarah
    Simonsen, Katy L.
    Sobiesk, Anne Marie
    Li, Bin
    Hodi, F. Stephen
    Long, Georgina, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (01) : 24 - 34
  • [10] PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
    West, Erin E.
    Jin, Hyun-Tak
    Rasheed, Ata-Ur
    Penaloza-MacMaster, Pablo
    Ha, Sang-Jun
    Tan, Wendy G.
    Youngblood, Ben
    Freeman, Gordon J.
    Smith, Kendall A.
    Ahmed, Rafi
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (06) : 2604 - 2615
1